EFFECTS OF THE DOPAMINE AGONIST CV 205-502 IN HUMAN PROLACTINOMAS RESISTANT TO BROMOCRIPTINE

被引:71
作者
BRUE, T
PELLEGRINI, I
GUNZ, G
MORANGE, I
DEWAILLY, D
BROWNELL, J
ENJALBERT, A
JAQUET, P
机构
[1] CHU LILLE, SERV ENDOCRINOL & DIABETOL, F-59037 LILLE, FRANCE
[2] INSERM, U159, UNITE NEUROENDOCRINOL, F-75005 PARIS, FRANCE
[3] HOP NORD MARSEILLE, SERV ENDOCRINOL, F-13326 MARSEILLE, FRANCE
[4] FAC MED NORD, INSERM, U297, MARSEILLE, FRANCE
[5] SANDOZ LTD, DEPT CLIN RES, CH-4002 BASEL, SWITZERLAND
关键词
D O I
10.1210/jc.74.3.577
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 21 patients with prolactinomas resistant to bromocriptine, we studied the effects of CV 205-502 on PRL hypersecretion and tumor mass, as assessed by consecutive computed tomography examinations. Cell culture studies were performed in 9 of such tumors. In 11 patients (group I; 52%) with a mean baseline plasma PRL level of 468 +/- 160-mu-g/L (+/- SE), normal PRL values were achieved after 1-6 months of treatment with 0.1-0.5 mg/day CV 205-502. Tumor size was reduced by 25% or more in 6 of 11 patients. In group II (n = 10), PRL levels (948 +/- 538-mu-g/L at baseline) were reduced by 48% after treatment with 0.1 mg/day CV 205-502. A progressive increase in the daily dose up to 0.5 mg did not further improve the partial reduction of PRL. No reduction in tumor size was observed in this group. The cell culture studies showed that 1) a brief exposure to both drugs provoked PRL suppression lasting 3 days; 2) in group I, CV 205-502 suppressed PRL release more efficiently than bromocriptine, with a maximal inhibition of 72% at 10(-9) mol/L; and 3) in group II, CV 205-502 only achieved a 26% inhibition of PRL release at 10(-8) mol/L, superimposable to that of bromocriptine. These data indicate that in at least half of such adenomas resistant to bromocriptine, CV 205-502, probably due to its higher affinity toward the D2 dopamine receptor, can overcome such resistance.
引用
收藏
页码:577 / 584
页数:8
相关论文
共 21 条
[1]   SELECTIVE DEFICIENCY OF GUANINE NUCLEOTIDE-BINDING PROTEIN G0 IN 2 DOPAMINE-RESISTANT PITUITARY-TUMORS [J].
COLLU, R ;
BOUVIER, C ;
LAGACE, G ;
UNSON, CG ;
MILLIGAN, G ;
GOLDSMITH, P ;
SPIEGEL, AM .
ENDOCRINOLOGY, 1988, 122 (03) :1176-1178
[2]   LONG-LASTING PROLACTIN-LOWERING EFFECT OF CABERGOLINE, A NEW DOPAMINE AGONIST, IN HYPERPROLACTINEMIC PATIENTS [J].
FERRARI, C ;
BARBIERI, C ;
CALDARA, R ;
MUCCI, M ;
CODECASA, F ;
PARACCHI, A ;
ROMANO, C ;
BOGHEN, M ;
DUBINI, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :941-945
[3]   HORMONAL EFFECTS OF CV 205-502, A NOVEL OCTAHYDROBENZO [G] QUINOLINE WITH POTENT DOPAMINE AGONIST PROPERTIES [J].
GAILLARD, RC ;
BROWNELL, J .
LIFE SCIENCES, 1988, 43 (17) :1355-1362
[4]  
GAILLARD RC, 1985, ENDOCRINOLOGY, P305
[5]   STIMULATION OF CORNEAL ENDOTHELIAL CELL-PROLIFERATION INVITRO BY FIBROBLAST AND EPIDERMAL GROWTH-FACTORS [J].
GOSPODAROWICZ, D ;
MESCHER, AL ;
BIRDWELL, CR .
EXPERIMENTAL EYE RESEARCH, 1977, 25 (01) :75-89
[6]  
GROSSMAN A, 1986, CLIN ENDOCRINOL OXF, V22, P611
[7]   HORMONAL-REGULATION OF PROLACTIN-RELEASE BY HUMAN PROLACTINOMA CELLS CULTURED IN SERUM-FREE CONDITIONS [J].
JAQUET, P ;
GUNZ, G ;
GRISOLI, F .
HORMONE RESEARCH, 1985, 22 (03) :153-163
[8]   HYPERPROLACTINEMIA - LONG-TERM EFFECTS OF BROMOCRIPTINE [J].
JOHNSTON, DG ;
PRESCOTT, RWG ;
KENDALLTAYLOR, P ;
HALL, K ;
CROMBIE, AL ;
HALL, R ;
MCGREGOR, A ;
WATSON, MJ ;
COOK, DB .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (05) :868-874
[9]   EFFECTS OF A NEW PROLACTIN INHIBITOR, CV 205-502, IN THE TREATMENT OF HUMAN MACROPROLACTINOMAS [J].
KHALFALLAH, Y ;
CLAUSTRAT, B ;
GROCHOWICKI, M ;
FLOCARD, F ;
HORLAIT, S ;
SERUSCLAT, P ;
SASSOLAS, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :354-359
[10]  
KUHN JM, 1985, PRESSE MED, V14, P525